Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011, Article ID 370872, 5 pages
http://dx.doi.org/10.1155/2011/370872
Clinical Study

Modulation of Cytokine and Cytokine Receptor/Antagonist by Treatment with Doxycycline and Tetracycline in Patients with Dengue Fever

1Centro de Investigaciones Regionales “Dr. Hideyo Noguchi”, Universidad Autónoma de Yucatan, 97000 Mérida, YUC, Mexico
2Facultad de Medicina, Universidad Autónoma de Yucatan, 97000 Mérida, YUC, Mexico
3Antibody Systems Inc., 1901 Norwood Drive, Hurst, TX 76054, USA

Received 3 August 2010; Revised 11 November 2010; Accepted 17 January 2011

Academic Editor: Ronald Herberman

Copyright © 2011 J. E. Z. Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Gubler, “Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century,” Trends in Microbiology, vol. 10, no. 2, pp. 100–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Pang, M. J. Cardosa, and M. G. Guzman, “Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS),” Immunology and Cell Biology, vol. 85, no. 1, pp. 43–45, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. G. Guzman and G. Kouri, “Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges,” Journal of Clinical Virology, vol. 27, no. 1, pp. 1–13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Marty, P. B. Jahrling, and T. W. Geisbert, “Viral hemorrhagic fevers,” Clinics in Laboratory Medicine, vol. 26, no. 2, pp. 345–386, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. V. Atrasheuskaya, T. M. Fredeking, and G. M. Ignatyev, “Changes in immune parameters and their correction in human cases of tick-borne encephalitis,” Clinical and Experimental Immunology, vol. 131, no. 1, pp. 148–154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. F. A. Bozza, O. G. Cruz, S. M. O. Zagne et al., “Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity,” BMC Infectious Diseases, vol. 8, pp. 86–93, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. B. Bethell, K. Flobbe, C. X. T. Phuong et al., “Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever,” Journal of Infectious Diseases, vol. 177, no. 3, pp. 778–782, 1998. View at Google Scholar · View at Scopus
  8. D. Hober, L. Poli, B. Roblin et al., “Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients,” American Journal of Tropical Medicine and Hygiene, vol. 48, no. 3, pp. 324–331, 1993. View at Google Scholar · View at Scopus
  9. S. Green, D. W. Vaughn, S. Kalayanarooj et al., “Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity,” Journal of Infectious Diseases, vol. 179, no. 4, pp. 755–762, 1999. View at Publisher · View at Google Scholar · View at PubMed
  10. C. Suharti, E. C. M. van Gorp, T. E. Setiati et al., “The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome,” Thrombosis and Haemostasis, vol. 87, no. 1, pp. 42–46, 2002. View at Google Scholar · View at Scopus
  11. M. Feldmann, “Many cytokines are very useful therapeutic targets in disease,” Journal of Clinical Investigation, vol. 118, no. 11, pp. 3533–3536, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. D. Phelan, T. Orekov, and F. D. Finkelman, “Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies,” Journal of Immunology, vol. 180, no. 1, pp. 44–48, 2008. View at Google Scholar · View at Scopus
  13. R. A. Ratsimandresy, J. Rappaport, and J. F. Zagury, “Anti-cytokine therapeutics: history and update,” Current Pharmaceutical Design, vol. 15, no. 17, pp. 1998–2025, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. C. Tauber and R. Nau, “Immunomodulatory properties of antibiotics,” Current Molecular Pharmacology, vol. 1, no. 1, pp. 68–79, 2008. View at Google Scholar · View at Scopus
  15. R. M. Bonelli, A. K. Hodl, P. Hofmann, and H. P. Kapfhammer, “Neuroprotection in Huntington's disease: a 2-year study on minocycline,” International Clinical Psychopharmacology, vol. 19, no. 6, pp. 337–342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. R. K. Zabad, L. M. Metz, T. R. Todoruk et al., “The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study,” Multiple Sclerosis, vol. 13, no. 4, pp. 517–526, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Stone, P. R. Fortin, C. Pacheco-Tena, and R. D. Inman, “Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity,” Journal of Rheumatology, vol. 30, no. 10, pp. 2112–2122, 2003. View at Google Scholar · View at Scopus
  18. A. Y. Lai and K. G. Todd, “Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines,” GLIA, vol. 53, no. 8, pp. 809–816, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. E. Girardin, P. Roux-Lombard, G. E. Grau, P. Suter, H. Gallati, and J.-M. Dayer, “Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia,” Immunology, vol. 76, no. 1, pp. 20–23, 1992. View at Google Scholar
  20. A. K. Lehmann, A. Halstensen, S. Sornes, O. Rokke, and A. Waage, “High levels of interleukin 10 in serum are associated with fatality in meningococcal disease,” Infection and Immunity, vol. 63, no. 6, pp. 2109–2112, 1995. View at Google Scholar · View at Scopus
  21. J. T. van Dissel, P. van Langevelde, R. G. J. Westendorp, K. Kwappenberg, and M. Frölich, “Anti-inflammatory cytokine profile and mortality in febrile patients,” Lancet, vol. 351, no. 9107, pp. 950–953, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. C. A. Dinarello, “Anti-cytokine therapeutics and infections,” Vaccine, vol. 21, no. 2, pp. S24–S34, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. B. J. Zheng, K. W. Chan, Y. P. Lin et al., “Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 23, pp. 8091–8096, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. E. A. Panacek, J. C. Marshall, T. E. Albertson et al., “Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels,” Critical Care Medicine, vol. 32, no. 11, pp. 2173–2182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. I. A. Clark, A. C. Budd, L. M. Alleva, and W. B. Cowden, “Human malarial disease: a consequence of inflammatory cytokine release,” Malaria Journal, vol. 5, pp. 85–117, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. A. Dinarello, “The biological properties of interleukin-1,” European Cytokine Network, vol. 5, no. 6, pp. 517–531, 1994. View at Google Scholar · View at Scopus
  27. J. H. Pruitt, M. B. Welborn, P. D. Edwards et al., “Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome,” Blood, vol. 87, no. 8, pp. 3282–3288, 1996. View at Google Scholar · View at Scopus
  28. J. M. Yang, Y. F. Chen, Y. Y. Tu, K. R. Yen, and Y. L. Yang, “Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors,” PLoS ONE, vol. 2, no. 5, pp. e428–e441, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus